Antibodies for Pets: PetMedix Raises $37M in Series B


PetMedix is a UK-based R&D stage veterinary therapeutics biotechnology company that has recently raised $37 million in a Series B funding round. This funding round’s participants included new investors. They are from the likes of Chinese multinational technology conglomerate Tencent and the Japanese corporation Kyoritsu Holdings. Furthermore, existing investors including US-based investor Digitalis Ventures, British funds Parkwalk Advisors, and Cambridge Innovation Capital.

Founded in 2018, PetMedix is using high-quality science to make medicines for pets. They claim that these will keep pets healthier, happier, and longer. Currently, they are the only company capable of making mature, fully species-specific antibodies. They use monoclonal antibodies, which are natural molecules th...

Login In


Register now for free access

Notify of
Inline Feedbacks
View all comments